A shocking 81% of people research online before making any buying decision. For London’s cosmetic practices, this means potential patients are searching everywhere – not just Google Maps. Yet most practices still rely solely on traditional local SEO, missing thousands of opportunities to connect with ready-to-buy patients.
The Local SEO Limitation Problem
Local SEO focuses on getting your practice to appear in Google’s local pack and Maps results. While this captures some traffic, it represents just a fraction of where your potential patients actually spend their research time. Think about it: when someone considers cosmetic surgery or advanced dental work, they don’t just check Google Maps and book immediately. They read articles, watch videos, listen to podcasts, and browse multiple platforms before making such an important decision.
Traditional local SEO also faces increasing competition. Every cosmetic practice in London is fighting for the same three local pack spots. Meanwhile, patients are researching on Business Insider, watching procedure videos on YouTube, listening to health podcasts on Spotify, and reading reviews across dozens of platforms you’ve never thought to target.
Understanding the “Search Everywhere” Approach
The “search everywhere” marketing method is a multimedia content marketing strategy focused on maximizing a brand’s visibility by ensuring its content appears across all relevant search platforms and channels—beyond just traditional search engines like Google. This involves creating content in a number of formats, including blogs, podcasts, infographics and videos.
The “search everywhere” method recognises that modern patient journeys happen across multiple touchpoints. Instead of competing for limited local search real estate, this approach positions your practice wherever patients are actively researching.
Here’s how the two strategies compare:
Local SEO typically focuses on Google My Business optimisation, local citations, and location-based keywords. It’s essential but limited in scope. “Search everywhere” marketing involves creating content in multiple formats and distributing this content across hundreds of platforms where your potential patients spend time.
The key difference lies in coverage. Local SEO might help you appear for “cosmetic dentist London” searches. “Search everywhere” helps you appear when someone reads about smile makeovers on major news sites, watches procedure videos, or listens to aesthetic health podcasts.
Which Approach Delivers Better Results?
The evidence suggests a combined approach works best, but if you had to choose one, “search everywhere” marketing often delivers superior results for cosmetic practices. One medical device company using this approach saw traffic increase by approximately 20,000% over twelve months, growing from £48,000 to £735,000 in monthly sales.
The reason is simple: when multiple respected platforms feature content about your services, both patients and search engines perceive your practice as more trustworthy and authoritative. This increased trust leads to more conversions and allows you to charge premium prices.
Expert Implementation Example
Companies like MedFire Media specialise in this “search everywhere” approach for London’s aesthetic healthcare sector. They create content across multiple formats and publish it on platforms including Business Insider, YouTube, Google News, and Apple Podcasts. Their artificial intelligence technology repurposes content efficiently, while professional writers ensure quality remains high.
Rather than competing for local search scraps, practices using this method appear wherever their potential patients research – from news articles to specialist podcasts. The result is typically increased map pack exposure, more phone calls, and improved overall search rankings.
Making the Right Choice for Your Practice
For London cosmetic practices, the choice isn’t really between local SEO and content marketing – it’s about understanding that today’s patients research across multiple platforms before making decisions. While maintaining your Google My Business presence remains important, limiting your marketing to local search alone means missing the majority of potential patient touchpoints.
Consider where your ideal patients spend their research time. Are they just checking Google Maps, or are they reading health articles, watching procedure videos, and listening to podcasts? The answer will guide your marketing strategy choice.
If you’re ready to explore how “search everywhere” multimedia content marketing could work for your London cosmetic practice, research providers who understand the aesthetic healthcare sector and can demonstrate real results across multiple platforms.
MedFire Media division of Logjam Solutions Limited
101 Woodsedge
Waterlooville
Hampshire
PO7 8PX
United Kingdom
Franchise Now recently featured Mosquito Shield in a powerful episode of Franchise Marketing Radio, offering an inside look at a brand that has quietly built one of the most durable and innovative models in home services franchising. With President Michael Moorhouse at the helm, Mosquito Shield continues to evolve with a focus on smart operational systems, year-round revenue strategies, and franchisee-first leadership. From its proprietary pest control formula to its latest venture into holiday lighting, Mosquito Shield presents a compelling story of strategic growth, technology adoption, and brand legacy.
This blog post distills key takeaways from that episode and unpacks how Mosquito Shield stands out in a saturated home services category.
Decades of Market Experience Provide a Foundation for Success
Founded in 2001, Mosquito Shield is not a newcomer to the pest control industry. It launched its franchise program in 2013 after more than a decade of market testing, product development, and customer feedback. That pre-franchise history matters. It means the company entered franchising with a proven operating system, high product efficacy, and a deep understanding of the homeowner demographic it serves.
This operational maturity is a direct result of the brand’s long-term leadership. Moorhouse, who has been with Mosquito Shield for over 17 years, has played a pivotal role in shaping the company’s trajectory—from grassroots service model to a franchise powerhouse. His hands-on experience during the brand’s foundational years continues to influence how franchisees are onboarded and supported today.
Unlike many pest control franchises that were created to capitalize on a growing niche, Mosquito Shield started as a service-first company that transitioned to franchising only after validating its results. The result is a brand with significant operational maturity, high customer retention rates, and a strong brand reputation—especially in the high-end residential segment.
The company’s approach is centered on service frequency and flexibility. While most competitors operate on rigid 21- or 30-day treatment cycles, Mosquito Shield customizes its schedule based on mosquito pressure and weather patterns. This real-time scheduling model delivers better results and higher customer satisfaction, leading to strong word-of-mouth referrals.
Visit the Franchise Now Media hub to hear the full episode and explore more growth-oriented franchise stories.
A Proprietary Formula and Smart Training Model Drive High Retention
One of Mosquito Shield’s most valuable assets is its proprietary pest control blend. Developed through years of experimentation, the formulation uses a mix of all-natural oils and other EPA-exempt ingredients. The result is a product that’s not only safe for families and pets but also remarkably effective at eliminating mosquito populations in residential environments.
Under Moorhouse’s leadership, the brand recently reinvested in this formula, conducting new lab testing and refinement to ensure it remains best-in-class. This ongoing innovation reflects the brand’s long-term commitment to quality and results, even when already performing at a high level.
This formulation, combined with weather-based scheduling, reduces the need for callbacks and retreatments—saving franchisees time and increasing customer trust. It’s a recurring revenue model that actually retains its base year after year, a rarity in home services where churn often runs high.
Customer retention rates consistently exceed 90%, thanks in part to the company’s emphasis on technician education. Each year, Mosquito Shield runs regional boot camps for new and returning technicians, covering everything from spray strategy and site inspection to customer interaction. These training events—strategically designed under Moorhouse’s guidance—ensure that each visit is conducted with professionalism and precision, reinforcing the brand’s value proposition.
A Strategic Alliance with Five Star Franchising Boosts Capabilities
Mosquito Shield’s growth trajectory was significantly enhanced in 2022 when the company was acquired by Five Star Franchising, a platform built by experienced franchise operators to scale leading home service brands. The acquisition opened up a wide range of resources to franchisees, including access to a robust IT infrastructure, expanded marketing services, franchise business coaches, and shared operational best practices.
Moorhouse has credited this partnership with accelerating the brand’s scalability, allowing Mosquito Shield to expand its internal team and implement operational improvements without sacrificing the personalized support franchisees expect. The alignment with Five Star has enhanced both service delivery and profitability at the local level.
Expanding Through Seasonal Services: The Launch of Decorate With Lights
To address the seasonality that comes with pest control services, Mosquito Shield’s leadership developed a complementary brand: Decorate With Lights. This holiday lighting franchise is designed to plug directly into the existing Mosquito Shield framework. It uses the same customer base, the same service teams, and the same branding strategy, while extending the franchisee’s earning window into fall and winter.
This dual-brand approach was envisioned and executed by Moorhouse and his team to solve for the winter revenue gap that many pest control businesses face. By leveraging Mosquito Shield’s affluent client base, franchisees can add a premium, seasonal service with minimal investment and maximum synergy.
The lighting service appeals to upscale homeowners who want high-end, custom lighting installed on their properties for the holidays. Franchisees consult with clients on the design, install the lighting in late fall, and return to take everything down in January—making it a tightly scheduled but highly profitable revenue stream.
Additionally, Decorate With Lights helps franchisees retain seasonal employees who would otherwise leave after the mosquito season ends. It’s a win-win for both owner and customer, offering consistency in service and additional income opportunities without significant incremental investment.
The company expects this line to double in footprint over the next 12 months, with more Mosquito Shield owners taking advantage of the built-in synergy between the two brands.
Marketing That Combines Grassroots Execution with Digital Precision
Mosquito Shield is not just tech-enabled—it’s marketing-savvy. Franchisees are trained to execute hyperlocal campaigns that combine physical visibility with digital presence. Branded vans, lawn signs, and door hangers are deployed in neighborhoods where services are being delivered. This visible presence not only creates brand awareness but reinforces legitimacy for potential customers.
Moorhouse has long emphasized a neighborhood-centric strategy, pairing traditional tactics with precision targeting through the company’s proprietary routing software. Franchisees are supported with digital campaigns, including PPC advertising and SEO strategies tailored to their geography and service season. The result is an omnichannel approach that captures attention online and reinforces trust offline.
Franchisees also benefit from advanced neighborhood targeting tools embedded in their routing software. These tools help identify postal routes where existing customers reside and generate direct mail pieces to surrounding households. The goal is to build route density—servicing more homes in fewer hours, which drives both revenue and margin improvements.
Technology That Supports Real-Time Decisions and Long-Term Growth
Operational efficiency is a cornerstone of the Mosquito Shield model. The company uses predictive weather modeling to inform franchisees when mosquito season is likely to begin in their region. This data not only informs marketing timelines but also helps owners schedule staff and prepare inventory before demand spikes.
Under Moorhouse’s leadership, this use of predictive analytics has expanded into neighborhood-level planning and seasonal optimization. The brand recently upgraded its route optimization system, making technician schedules more efficient and reducing time spent per visit. These improvements allow franchisees to serve more customers each day without sacrificing service quality.
This continual focus on improvement has led to the brand reformulating its proprietary blend in the past year based on lab findings—despite already having a best-in-class product. It’s this attention to innovation that keeps the brand ahead of its peers and fuels franchisee growth.
Territory Planning and Owner Support Create Scalable Outcomes
Mosquito Shield’s franchise development team uses detailed mapping software to define territories based on household demographics, income levels, and housing density. Franchisees don’t just receive a territory—they receive a data-informed opportunity.
Once a territory is assigned, marketing teams work with new owners to identify top-performing neighborhoods to focus their launch efforts. These first areas are selected to generate strong early traction and create a snowball effect as referrals and repeat business kick in.
Franchisees also benefit from business coaching, operational oversight, and access to field experts. Moorhouse and his leadership team have made franchisee success a strategic priority, with a clear directive that every initiative must drive value and accountability at the local level. This ecosystem of support is essential to helping owners grow from startup to scale, especially in their first 24 months.
A Franchise for Builders, Leaders, and Community Connectors
Mosquito Shield attracts franchisees who are serious about delivering quality service and building meaningful businesses. While prior experience in pest control isn’t required, the brand seeks candidates who are willing to follow systems, manage people, and stay involved in daily operations—especially during the ramp-up phase.
Owners can choose to remain single-territory operators or expand to multiple units. Some exit after a decade with life-changing capital events, while others choose to scale across regions. Under Moorhouse’s tenure, the brand has seen early adopters grow into seasoned operators, many of whom are now achieving successful exits that reflect the equity and value created through long-term brand alignment.
With high retention, dual-service opportunities, and unmatched training, Mosquito Shield continues to set a new standard for franchise performance in the home services space.
Conclusion
The latest episode of Franchise Marketing Radio offers a rare look inside a brand that has quietly outpaced many of its competitors. From its real-time service delivery and proprietary formulations to its seasonal expansion and AI-powered routing systems, Mosquito Shield is more than just a pest control company—it’s a franchise growth engine. For entrepreneurs seeking a model that combines legacy, technology, and scalable operations, this episode serves as both a blueprint and a call to action. Visit Franchise Now for further insights.
Franchise Now
860 Robbie View
Suite 1031
Colorado Springs
CO
80920
United States
Strategic Partnership to Establish Cambridge Isotope Laboratories, Pvt. Ltd. in Hyderabad’s Genome Valley, Enhancing Global Production and Supply of Isotopically Enriched Chemical Solutions for Pharmaceutical and Electronics Industries
TEWKSBURY, MA AND HYDERABAD, INDIA / ACCESS Newswire / October 27, 2025 / Cambridge Isotope Laboratories, Inc. (CIL), and Chemtatva Chiral Solutions, Pvt. Ltd. (CCS), a leading provider of chiral and specialty chemical solutions, announce the execution of a signed Memorandum of Understanding to establish Cambridge Isotope Laboratories, Pvt. Ltd. in Hyderabad, India. This initiative marks a milestone in the expansion of CIL’s global footprint and further enhances capabilities in the development and production of deuterated reagents and other isotopically enriched products. This partnership will enhance global supply chain strength and real-time support for customers in Asia and enable multi-site production for global customers focused on business continuity. The forthcoming entity, Cambridge Isotope Laboratories, Pvt. Ltd., is expected to be officially established in Q4 2025, subject to customary diligence and closing considerations. Operations for the newly formed entity will be initiated at existing CCS facilities, with a net new facility slated for groundbreaking in 2026. The new facility will be located in India’s Genome Valley, a burgeoning 2,000-acre life sciences cluster located in suburban Hyderabad.
Cliff Caldwell, CEO at CIL noted, “We are excited to partner with CCS to combine our chemistry expertise and pursue scale-up technologies to further support pharmaceutical and industrial applications. This initiative reflects our commitment to supporting global research and development efforts in scientific fields as well as supporting the growing commercial needs for deuterium labeled and specialty chemical products in the pharmaceutical and electronics industries.”
Vishal Rajput, CEO of CCS said, “The collaboration and newly formed entity will leverage CCS’s strong infrastructure and deep technical capabilities in India, while integrating CIL’s world-class standards in isotope chemistry, quality systems, global logistics and go-to market capabilities.” Mr. Rajput will lead the newly formed entity as general manager of Cambridge Isotope Laboratories, Pvt. Ltd. The legacy CCS business will remain intact, with the collective intent to expand access to high quality, isotopically labeled and unlabeled compounds for customers worldwide, with an emphasis on downstream synthetic compounds and a commitment to industry-specific product quality requirements.
All CIL, Eurisotop and CCS branded and manufactured materials remain available to Indian and worldwide customers through existing channels. Further details regarding the launch and operational scope of Cambridge Isotope Labs Pvt. Ltd. will be shared in the coming months.
About Cambridge Isotope Laboratories, Inc. CIL, a subsidiary of Otsuka Pharmaceutical in Japan, is the largest manufacturer and global supplier in the world of stable isotopes and stable isotope‑labeled compounds. Trusted by industrial and academic collaborators since 1980, CIL’s products are used in research, diagnostics, environmental, pharmaceutical, medical diagnostic, OLED, and industrial applications. CIL’s operations include two facilities in the Boston, MA, area; a large isotope‑enrichment production plant in Xenia, OH; CIL China; CIL Canada; ABX in Dresden, Germany (specializing in radioisotopic‑labeled compounds for cancer diagnosis and treatment); and Eurisotop in Saclay, France.
About Chemtatva Chiral Solutions, Pvt. Ltd. CCS is a Hyderabad-based company founded in 2021, specializing in chiral chemistry, process development, and custom synthesis for pharmaceutical and chemical industries. CCS is a trusted global partner in life sciences, delivering innovative chemistry solutions that solve complex challenges and accelerate scientific progress.
SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be presenting on Monday, October 27th, at 03:00pm at the PODD 2025 Conference in Boston, MA.
Event Information:
Event
NanoViricides Presentation at the PODD 2025, Boston, MA
Track
5A
Date
Monday, October 27, 2025
Time
03:00 pm
Location
St. George, ABC, at Westin Copley Hotel, Boston, MA
Anil R. Diwan, PhD, President and Executive Chairman of the Company will provide an update on the Company, its Drug Pipeline and Platform Technologies available for licensing.
NanoViricides’ Current Antiviral Drugs Pipeline
NanoViricides lead clinical stage drug candidate NV-387 is rapidly moving into Phase II for the treatment of MPox in the Democratic Republic of Congo.
A separate Phase II clinical trial for the evaluation of NV-387 as a first line therapy of any respiratory viral infection (NV-387 for the treatment of Viral Acute or Severe Acute respiratory Infections, Viral ARI/SARI, is being planned. Success in this clinical trial would enable NV-387 to become the first ever antiviral drug that can be prescribed by a physician based on symptoms, as an emperic therapy for respiratory viral infections, without having to test for which virus is causing the disease.
The revolutionary broad antiviral spectrum of NV-387 is reminiscent of the dawn of antibiotics to combat bacterial infections.
NV-387 was found to be highly effective against the “tripledemic” respiratory viruses, namely RSV, Influenza A, and Coronaviruses, in respective lethal animal models of lung infection. NV-387 was found to be substantially superior to existing drugs, and even resulted in complete cure in the RSV animal study. These studies prompted evaluation of NV-387 as a first line therapy of respiratory viral infections.
There is no treatment approved for RSV.
NV-387 has shown excellent effectiveness in lethal lung infection animal models relevant for Smallpox and MPox viruses.
There is no treatment approved for MPox; tecovirimat (TPOXX) has failed clinical trials, and no results are available from the brincidofovir (TEMBEXA) clinical trial “MOSA”.
Additionally, NV-387 has shown excellent effectiveness against Measles virus lethal lung infection in a humanized (hCD150+ knock-in) mouse model.
There is no treatment approved for Measles. Cases of Measles have been rapidly rising in the developing world including USA, Canada, UK and European countries. Measles is an important health threat because the disease can lead to “immune amnesia”, wiping out pre-developed immunity against other diseases, because it attacks the immune system itself.
The nanoviricides™ platform technology is yielding novel antiviral drug candidates against a number of challenging viral targets at a rapid pace.
Our most advanced candidate, NV-387, is an ultra-broad-spectrum antiviral with potential activity against most respiratory human pathogenic viruses – and more, because it emulates the attachment receptor family of sulfated proteoglycans that over 90% of human viruses utilize.
Moreover, NV-387 is designed to shape-shift upon binding to the virus particle, in the process disrupting the virus particle and making it incapable of infection, as a complete chemical nanomachine that destroys the virus.
Viruses are unlikely to escape NV-387 because no matter how much a virus evolves, it continues to utilize and require binding to sulfated proteoglycans – the very characteristic that NV-387 emulates. This solves the long-standing problem of antiviral medicines, that viruses escape them. Vaccines, antibodies and small chemical drugs are readily escaped by viruses as the viruses evolve in the field. This has been repeatedly observed during the recent COVID-19 pandemic, as well as in the course of most of the other viral epidemics including Influenza and HIV/AIDS.
Continued redevelopment or “updating” of vaccines necessitated by the viral escape or drift has recurrently cost billions of dollars every year for Influenza as well as COVID. NV-387 promises to make such costly endeavors unnecessary, once this drug is approved by regulatory bodies.
NV-387 is rapidly moving towards Phase II Safety, Tolerability and Efficacy Evaluation for the Treatment of MPOX disease, in response to the continuing Public Health Emergency of International Concern in WHO African Region. We already have received preliminary approval of the clinical protocol and the study and now we are working diligently to finish and submit the clinical trial application.
The overall market size of NV-387 indications is estimated to be well in excess of $10 billion.
In addition, the Company has developed a clinical-ready pan-herpesvirus drug candidate, NV-HHV-1 that has shown activity against HSV-1, HSV-2 and VZV, and is expected to have activity against CMV, HHV-6, and HHV-8 as well.
The Company has also developed an anti-HIV drug candidate, NV-HIV-1, that has shown strong efficacy in SCID-hu-Thy-Liv animal model of HIV infection. NV-HHV-1 mimics the landing site on cellular CD4 that is required for all HIV viruses to cause cellular infection. Thus, HIV, despite constant changes, will be unable to escape NV-HHV-1.
NanoViricide Platform Enables Drug Rescue, Oral Drug Delivery, and Zip-Code Specific Delivery
Oral drug delivery of small chemicals, peptides (such as the GLP-a obesity drugs), and proteins is feasible by encapsulation of the guest drug into the nanoviricide polymeric micelle. The encapsulation protects the guest from metabolism thereby enabling effective drug delivery.
Encapsulation of a difficult or failed drug within the nanoviricide polymeric micelle can enable rescue of the drug candidate turning it into a clinically viable drug candidate, saving hundreds of millions of dollars of development work.
Going another step further, the nanoviricide platform technology can be customized to enable zip-code-like specific delivery of encapsulated drugs to specific tissues (e.g. non-liver targeted delivery),, cells (e.g. cancer-cell specific delivery sparing normal cells), bacteria, or viruses (e.g. NV-HHV-1, NV-HIV-1) in a fully synthetic chemistry based, scalable technology stack.
Pharma, biotech and drug delivery industries will gather at the 15th annual PODD event to assess delivery needs, explore partnership opportunities, and stay at the forefront of innovative drug delivery technologies. This includes small molecules, biologics, combination products, connected devices, cell and gene delivery and more.
PODD provides partnering opportunities through organized networking for new, emerging and established collaborations.
NanoViricides, Inc. (the “Company”) ( www.nanoviricides.com ) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.
The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.
NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.
FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.
NORTH YORK, ON / ACCESS Newswire / October 27, 2025 / ZTEST Electronics Inc. (“ZTEST” or the “Company“) (CSE:ZTE)(OTCID:ZTSTF) announces fiscal 2025 revenues of $8,319,302, including $2,113,637 in Q4, representing the third consecutive quarter with very modest revenue growth. Revenues for the corresponding periods of 2024 were $9,756,044, inclusive of the record revenues of $2,791,359 in the final quarter.
Financial Highlights
Fiscal Year End
(in thousands of dollars, except per share amounts)
June 2025
June 2024
Revenue
8,319
9,756
Gross Margin
3,457
3,918
Gross Margin as a % of Revenue
41.6
40.2
Net Income
1,089
1,753
Net Income per share (basic)
0.030
0.058
EBITDA
1,837
2,599
Operating Cash Flow
1,657
2,280
Financial Position
As at
(in thousands of dollars)
Jun 30 2025
Jun 30 2024
Cash
4,105
2,776
Working Capital
5,008
3,593
Long-term Debt
56
121
Shareholders’ Equity
5,807
4,497
Financial Highlights
Three months ended
(in thousands of dollars, except per share amounts)
Dec 31 2025
Dec 31 2024
Revenue
2,114
2,791
Gross Margin
872
1,171
Gross Margin as a % of Revenue
41.3
41.9
Net Income
300
546
Net Income per share (basic)
0.008
0.016
EBITDA
494
870
Operating Cash Flow
415
809
Steve Smith, CEO commented, “The EMS market entered a cyclical decline in the second half of fiscal 2024 and the imposition and threat of tariffs added to the market malaise. As a contract assembler our business levels tend to trail general market swings leading to a strong finish to fiscal 2024 followed by generally smaller orders in fiscal 2025. We realized modest revenue growth in each of the final three quarters of 2025 and are very encouraged by the positive signs that began in the latter part of the third quarter of 2025, both domestic and export, suggesting that market confidence is returning. We believe that our extensive efforts to nurture existing customer relationships, and foster new customer relationships, is starting to pay off.”
The Company also wishes to announce that Steve Smith, Dean Tyliakos, David Barnett and William R. Johnstone were re-elected to the Board of Directors and Kreston GTA LLP, Chartered Professional Accountants, were re-appointed as auditors of the Company for the ensuing year at the annual meeting of shareholders held on Friday October 24, 2025.
About ZTEST Electronics Inc.
ZTEST Electronics Inc., through its wholly owned subsidiary Permatech Electronics Corporation (“Permatech”), offers Electronic Manufacturing Services (EMS) to a wide range of customers. Permatech’s offering includes Printed Circuit Board (PCB) Assembly, Materials Management and Testing services. Permatech operates from an ISO 9001:2015 certified facility in North York, Ontario, Canada. Permatech is a contract assembler of complex circuit boards, serving customers in the Medical, Power, Computer, Telecommunications, Wireless, Industrial, Trucking, Wearables and Consumer Electronics markets. It specializes in servicing customers who are looking for high yield and require high quality and rapid-turnaround on low and mid-volume production of high complexity products.
For more information contact: Steve Smith, CEO (604) 837-3751 email: steves@ztest.com
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
FORWARD LOOKING STATEMENTS: This press release contains forward looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Investors are cautioned that these forward-looking statements are neither promises nor guarantees and are subject to risks and uncertainties that may cause future results to differ materially from those expected. These forward looking statements are made as of the date hereof and, except as required under applicable securities legislation, the Company does not assume any obligation to update or revise them to reflect new events or circumstances. All of the forward-looking statements made in this press release are qualified by these cautionary statements and by those made in our filings with SEDAR+ in Canada (available at www.sedarplus.com).
Oct. 26, 2025 / PRZen / ALTMUNSTER, Austria — Uniform refrigerant distribution and effective condensate drainage have long been among the main engineering challenges in microchannel evaporator design. While Kaltra’s previous coil generations successfully solved these aspects individually, certain demanding conditions — such as low-load operation, frosting, or use in reversible heat-pump systems — continued to push design limits.
Driven by the goal of achieving flawless performance under all operating scenarios, Kaltra’s R&D team has taken the technology a step further. The result is a new, revolutionary generation of microchannel evaporator coils that ensure stable operation under the most challenging thermal conditions and enable full reversibility as condenser coils in heat-pump applications.
The breakthrough comes with a configuration that places the microchannel tubes horizontally — a layout traditionally avoided in evaporator designs due to poor condensate drainage. Kaltra’s engineers overcame this limitation by replacing individual folded fin stripes with vertical louver-fin plates with leading edges. These edges, which maintain a higher surface temperature than the flat tube, slow the cooling process and direct the formed condensate efficiently downward, ensuring complete drainage and improving frost management and de-icing performance.
With the new vertical louvered-fin plates, condensate drainage and coil behavior under frosting conditions closely match that of conventional finned-tube coils, as the fin geometry of Kaltra’s new evaporator coils closely resembles that of traditional designs — while retaining all the advantages of microchannel technology.
The new horizontal-tube arrangement additionally allows for multi-pass refrigerant circuitry, delivering higher overall heat-transfer performance and superior efficiency in reversible (condenser) operation.
Another key innovation lies in the manifold design. The manifolds feature a special internal geometry with intermediate orifice plates, which promote turbulent mixing of the refrigerant’s gas and liquid fractions. This improves uniformity of refrigerant across all microchannel tubes, ensuring consistent thermal performance and preventing the formation of superheated regions.
The circuit geometry has also been optimized by adjusting the number of tubes in each refrigerant pass, improving overall coil performance for both evaporator and condenser modes. With this design, Kaltra achieves an optimal balance between evaporator and condenser performance, ensuring high efficiency and stable operation in reversible systems.
This latest coil generation was developed with a clear focus on heat pump applications, one of the fastest-growing segments in HVAC technology. Reliable reversibility, consistent drainage under frosting conditions, and minimized pressure drop make these coils an ideal choice for modern heat pump systems that must maintain performance across a wide range of ambient conditions. Extensive laboratory and field testing have confirmed the coils’ outstanding performance under repeated frosting and defrosting cycles.
The organic skincare and holistic wellness brand has gained significant consumer recognition due to its innovative formulations and commitment to quality. With a focus on natural ingredients and sustainable practices quickly establishing a strong presence in the market.
Oct. 25, 2025 / PRZen / MURPHY, N.C. — Wild Hermit Wellness is quickly establishing itself as a beacon of hope in the skincare industry, championing affordable holistic wellness and the embrace of natural beauty. Since its launch two months ago, the brand has garnered global attention for its innovative approach to skincare and hair care, centering on goat milk and eco-friendly, natural ingredients. Wild Hermit Wellness offers a carefully curated range of organic products designed for eco-conscious consumers who value both efficacy and ethical standards.
The inception of Wild Hermit Wellness by founders Samantha and T. Craig McManus was inspired by the increasing awareness among consumers about the ingredients in their personal care products. Recognizing a gap in the market for products that are both effective and environmentally responsible, the founders, alongside a dedicated team, have crafted a line of skin-nourishing and eco-friendly solutions. Their commitment to sustainability and reverence for Earth’s natural resources drives their mission.
Each product is made from organic ingredients—free from sulfates, parabens, and phthalates—ensuring gentleness for both skin and planet. The use of natural retinol and chemical-free anti-aging alternatives distinguishes Wild Hermit Wellness as a luxurious yet ethical choice. Their globally lauded bestseller, the Organic Goat Milk & Okra Peptide Shampoo and Conditioner Bundle, exemplifies their innovative spirit, designed to rejuvenate scalp, roots, and strands.
Wild Hermit’s success story is not just about products but about transformation—both for its customers and the wider beauty industry. It heralds a future where sustainable, natural beauty is not merely a trend but a lasting commitment. This ethos is encapsulated in their motto: “Sustainable, Eco-Friendly, Always Organic.”
Samantha and Craig McManus state, “At Wild Hermit Wellness, we believe in the harmony between nature and self-care. Our dedication to sustainability and the earth’s bounty is woven into every product we create.”
As the holiday season approaches, Wild Hermit is delighted to announce a special sale on their Etsy store and website, featuring their new Lineage Line, among other cherished collections. Additionally, they offer custom exotic woodworking gifts and handmade pottery, perfect for holiday gifting.
Nestled in the Appalachian Mountains, Wild Hermit was born from a profound connection to nature and a desire to create from the heart. Their bestselling books and holistic wellness programs further reflect their commitment to fostering a community centered around wellness.
For more information about Wild Hermit Wellness and their offerings, visit their website at https://www.wildhermit.com, explore their Etsy store, or delve into their educational resources at https://www.semcmanus.com.
About Wild Hermit Wellness:
Wild Hermit is dedicated to crafting naturally derived beauty and wellness products. Prioritizing sustainability and the interconnectedness of life, they create with excellence and innovation to enhance well-being through organic care.
Vancouver, WA October 26, 2025 –(PR.com)– ETC Mining, a global cloud computing platform focused on clean-energy operations, today announced the launch of a new mobile app designed to provide users with a more convenient way to participate in cloud mining. Through this mobile tool, users can manage mining contracts anytime and anywhere, monitor computing performance in real time, and track revenue.
Meeting Global Demand for Green Cloud Mining
The launch of this mobile app follows growing global interest in blockchain and sustainable mining models. As major digital assets such as XRP, BTC, and ETH continue to attract attention as part of the broader digital-asset economy, ETC Mining states that its mobile solution aims to offer a transparent and environmentally conscious approach to cloud mining.
Technology-Driven Simplified Experience
Founded in 2019 and headquartered in the UK, ETC Mining reports that it operates data centers in regions including Eastern Europe, North America, Central Asia, and Australia. The platform provides computing power support through distributed infrastructure and artificial-intelligence scheduling designed to optimize resources for BTC, ETH, LTC, ETC, and other networks.
An ETC Mining spokesperson said:
“Our goal is to make cloud mining easier to manage and more transparent. The mobile app provides users with accessible tools and improved control over their mining activities.”
Security and Sustainability
ETC Mining’s security framework includes SSL encryption and distributed server redundancy to help protect data and transactions. The company also reports ongoing investment in renewable-energy infrastructure, such as solar and wind power, to support the sustainability of its cloud-mining operations.
Southport, CT October 26, 2025 –(PR.com)– Last night, October 23, Family Law Firm Conlon Amendola, in partnership with MoCACT, hosted a vibrant event at their elegant Southport offices to celebrate the 49th year of the Heida Hermanns International Music Competition.
The event drew renowned attorneys, art collectors, and VIPs, who savored delicacies from a “jaw droppingly beautiful” grazing table as well as a selection of passed hors d’oeuvres by A&S Westport Catering & Events.
“The Heida” competition, a prestigious platform for pianists aged 18-30 worldwide, was highlighted with remarks by “Heida” champion Kristin Foster, a member of MoCACT Board of Directors and Performing Arts Advisory Committee, as well as the presence of longtime “Heida” benefactors, Suzanne and Norman Sorensen.
“My wife Suzanne and I have supported MoCACT and the Heida Hermanns competition for ten years, and it’s been a true privilege,” said Sorensen. “MoCACT has done commendable work in attracting young, aspiring artists.” In his remarks, Mr. Sorensen emphasized the need for increased funding to sustain opportunities for talented musicians who lack resources to showcase their skills.
Dr. Joan Miller of Capital Prep Harbor School shared heartfelt insights, noting the competition’s impact on inner-city youth by exposing them to transformative cultural experiences. “On the bus ride home after the performance, the children’s faces lit up as they discussed the pianists’ hand movements and the music’s emotional impact,” she remarked. “Some of our children have never left Bridgeport, and giving them the opportunity to see what’s possible was wonderful.” Dr. Miller concluded, “I’d love to do it again. I hope the partnership will continue for years to come.”
The evening underscored the vital role of local businesses in supporting arts and culture. Family Law attorneys Jacquelyn Conlon and Bonnie Amendola, hosts of the event, summed up the sentiment: “We believe it’s important to support MoCA and ‘The Heida’ to keep creativity alive, challenge our perspectives, create opportunities for those in need, and ensure all artists have the freedom to keep moving culture forward.”
The event was a resounding success, shining a spotlight on the importance of community-driven cultural initiatives.
Seattle, WA October 26, 2025 –(PR.com)– MSP Miner, a technology company focused on sustainable blockchain infrastructure, has announced the launch of its next-generation cloud mining platform. Founded in 2018 and headquartered in the United Kingdom, MSP Miner operates global data centers powered by renewable energy sources. The platform aims to make cryptocurrency mining accessible to users worldwide—requiring only a smartphone or computer, without the need for specialized hardware or technical expertise.
Making Mining More Accessible
As the cryptocurrency market evolves, Ethereum (ETH), Dogecoin (DOGE), and Ripple (XRP) continue to hold strong positions among mainstream digital assets. At the same time, energy-efficient cloud mining has emerged as a sustainable and lower-barrier method for users to participate in blockchain validation.
Unlike traditional mining, cloud mining allows participants to remotely lease computing power instead of purchasing and maintaining costly hardware. Users can monitor mining activity through MSP Miner’s online dashboard and manage contracts conveniently from their mobile devices.
Security, Efficiency, and Sustainability
MSP Miner emphasizes transparency, environmental responsibility, and system security. The company states that its facilities use renewable energy—including solar, wind, and hydropower—to reduce carbon emissions and support sustainable blockchain operations.
MSP Miner states that the key features of its platform include:
1. Security and Stability: MSP Miner utilizes McAfee® and Cloudflare® security technologies, combined with cold-storage digital wallets, to help safeguard assets and data.
2. Green Infrastructure: Operations are powered entirely by renewable energy sources for a reduced environmental footprint.
3. User Transparency: The platform provides accessible information on data center operations and mining performance metrics.
4. Smart Operations: Automated management tools allow users to track contract activity and performance metrics in real time.
5. Multi-Currency Support: Users can select mining contracts linked to various digital assets, including BTC, ETH, DOGE, SOL, XRP, USDC, LTC, and USDT.
6. Referral Program: MSP Miner offers optional referral incentives for users who introduce new participants to the platform.
To begin, users can register through the official MSP Miner website and explore available contract options. Each plan is tailored to different budgets and time frames, offering flexibility for individuals interested in participating in remote mining operations.
After registration, users can monitor mining activity and review results through the platform’s dashboard. MSP Miner provides customer support and educational resources to help users understand how cloud mining works and the risks associated with cryptocurrency markets.
About MSP Miner
Established in 2018, MSP Miner focuses on providing technology solutions for cloud-based digital asset mining. Its mission is to promote environmentally friendly mining practices and make blockchain participation accessible to a wider audience.
A shocking 81% of people research online before making any buying decision. For London’s cosmetic practices, this means potential patients are searching everywhere – not just Google Maps. Yet most practices still rely solely on traditional local SEO, missing thousands of opportunities to connect with ready-to-buy patients.
